Lexicon for Clonal Hematopoiesis in Liquid Biopsy
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Robert Tell und 21 weiteren Autor:innen. Beteiligte Einrichtung: Tempus AI, Inc., Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Cell-Free Nucleic Acids, Clonal Hematopoiesis, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Historically, clonal hematopoiesis (CH) has been recognized as a confounder of cell‐free DNA (cfDNA) testing. Recent evidence now demonstrates the role of CH as a risk factor in health, generating distinct sources of cfDNA that can be leveraged for liquid biopsy diagnostics. Nonetheless, gaps in standardization challenge the advancement of such diagnostics from development to regulatory approval, through clinical trials, and ultimately, to routine implementation. In 2024, the Blood Profiling Atlas in Cancer (BLOODPAC) Consortium, a collaborative infrastructure for developing standards and best practices for liquid biopsy assays, established the CH/clonal hematopoiesis of indeterminate potential (CHIP) Working Group to address the need for accurate identification and removal of CH from liquid biopsy results. As a first step to support the interpretability of CH/CHIP results, the Working Group developed this lexicon to standardize terms and provide a unified vocabulary related to CH and liquid biopsy, DNA sequencing tests, biomarkers, and clinical use cases, facilitating communication within the field. BLOODPAC's CH/CHIP Working Group believes that terminology agreement across these various stakeholders can improve communication in the field and unify future data collection efforts across studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tempus AI, Inc., Chicago, Illinois, USA.
- Natera, Austin, Texas, USA.
- LGC Clinical Diagnostics, Milford, Massachusetts, USA.
- Exact Sciences, Madison, Wisconsin, USA.
- School of Life Sciences, Arizona State University, Tempe, Arizona, USA.
- Delfi Diagnostics, Baltimore, Maryland, USA.
ORCID-Profile: Robert Tell, Ahmet Zehir, Andrew T Anfora, Gargi Basu, Michelle Beidelschies, Carolyn Compton, Stephen Cristiano, James H Godsey, John Hu, Donald J Johann, Marisa Juntilla, Rina Kansal, Dorys Lopez Ramos, Vaidhyanathan Mahaganapathy, Christian Rolfo, Daniel Stetson, Martin You, Lauren C Leiman
Zitieren
APA
Tell, R., Zehir, A., Anfora, A. T., Basu, G., Beidelschies, M., Compton, C., Cristiano, S., Godsey, J. H., Hu, J., Johann, D. J., Juntilla, M., Kansal, R., Lo, C., Lopez Ramos, D., Mahaganapathy, V., Merriam, D., Rolfo, C., Russell, H., Singh, U., …, & Leiman, L. C. (2026). Lexicon for Clonal Hematopoiesis in Liquid Biopsy. Clinical and Translational Science. https://doi.org/10.1111/cts.70463
Vancouver
Tell R, Zehir A, Anfora AT, Basu G, Beidelschies M, Compton C, et al. Lexicon for Clonal Hematopoiesis in Liquid Biopsy. Clinical and Translational Science. 2026. doi:10.1111/cts.70463
BibTeX
@article{Tell2026,
author = {Tell, Robert and Zehir, Ahmet and Anfora, Andrew T and Basu, Gargi and Beidelschies, Michelle and Compton, Carolyn and Cristiano, Stephen and Godsey, James H and Hu, John and Johann, Donald J and Juntilla, Marisa and Kansal, Rina and Lo, Christine and Lopez Ramos, Dorys and Mahaganapathy, Vaidhyanathan and Merriam, David and Rolfo, Christian and Russell, Hugh and Singh, Usha and Stetson, Daniel and You, Martin and Leiman, Lauren C},
title = {Lexicon for Clonal Hematopoiesis in Liquid Biopsy},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70463}
}
EUVIMED